There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to improve drug development by speeding up clinical trial recruitment. Dubbed Muse, the tool aims to cut the time it takes for recruitment strategy and content creation to just minutes, according to a Nov. 12 release. The program taps into several OpenAI models and can be used across a wide range of therapeutic indications. Both Big Pharma Sanofi and AI-focused biotech Formation Bio plan on using Muse in upcoming clinical trials, with an initial rollout expected for phase 3 tests of Sanofi’s multiple sclerosis meds. Here’s how the tool is designed: First, Muse compiles in-depth research on diseases, patient demographics and the therapeutic landscape. Next, Muse analyzes the information to identify ideal patient profiles and recruitment strategies that include diverse populations. Finally, the tool auto-generates recruitment materials and prescreening questionnaires that are customized to specific patient subgroups and can be translated into different languages and styles. Additionally, Muse takes regulatory guidelines into consideration, with the goal of generating high-quality materials that comply with best practices. Data privacy is also embedded throughout Muse’s deployment, according to the release.

Full report : Sanofi, Formation and OpenAI to collaborate for artificial intelligence powered tool and speed up clinical trial timelines.